PureTech bags $200M from sale of Karuna shares — still sizzling from promising schizophrenia data

Amber Tong

Senior Editor

Cashing in on the exuberance around Karuna Therapeutics and its potential blockbuster CNS drug, PureTech has sold a chunk of the biotech’s shares to Goldman Sachs for $200 million.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

PureTech bags $200M from sale of Karuna shares — still sizzling from promising schizophrenia data

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Gilead leans on CymaBay liver drug, Trodelvy readouts and long-active PrEP yet to come this year

GSK accuses Pfizer and BioNTech of mRNA patent infringement

Bristol Myers outlines ‘about 12’ pipeline cuts as it executes major cutbacks

Updated: Bristol Myers plans $1.5B in cost cuts, including 2,200 jobs, as CEO promises more ‘agile’ company

PureTech bags $200M from sale of Karuna shares — still siz­zling from promis­ing schiz­o­phre­nia da­ta

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

Benchling

San Francisco, CA, USA

PureTech bags $200M from sale of Karuna shares — still sizzling from promising schizophrenia data